Intravenous amiodarone treatment in horses with chronic atrial fibrillation

Veterinary Journal

Volumn 172, Issue 1, 2006, Pages 129-134

  De Clercq, D ^a   van Loon, G ^a   Baert, K ^a   Tavernier, R ^b   Croubels, S ^a   De Backer, P ^a   Deprez, P ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Amiodarone; Atrial fibrillation; Chronic; Horse; Intravenous

Indexed keywords

AMIODARONE; BILIRUBIN;

ARTICLE; BLOOD ANALYSIS; CARDIOVERSION; CASTRATION; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EPISTAXIS; EXERCISE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HORSE; HORSE DISEASE; HYPERBILIRUBINEMIA; MUSCLE WEAKNESS; NONHUMAN; SINUS RHYTHM; SYMPTOM; WEIGHT BEARING;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; HORSE DISEASES; HORSES; SAFETY; TREATMENT OUTCOME;

EQUIDAE;

EID: 33744923440     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2005.04.001     Document Type: Article

References (40)

1. Agozzino F., Picca M., and Pelosi G. Acute hepatitis complicating intravenous amiodarone treatment. Journal of the Italian Heart 3 (2002) 686-688
2. Anderson J.L. Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management. Journal of Cardiovascular Electrophysiology 6 (1995) 880-886
3. Anon., 2002. Commission Decision of 12 August 2002, implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results, 2002/657/EC. Official Journal of the European Community, L221/8.
4. Balser J.R., Bennett P.B., Hondeghem L.M., and Roden D.M. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circulation Research 69 (1991) 519-529
5. Besser R., Treese N., Bohl J., and Goebel H.H. Clinical, neurophysiologic and biopsy findings in neurotoxic amiodarone syndrome. Medizinische Klinik 89 (1994) 367-372
6. Canada A.T., Lesko L.J., Haffajee C.I., Johnson B., and Asdourian G.K. Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. Drug Intelligence and Clinical Pharmacy 17 (1983) 100-104
7. Chow M.S. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Annals of Pharmacotherapy 30 (1996) 637-643
8. Deem D.A., and Fregin G.F. Atrial fibrillation in horses: a review of 106 clinical cases, with consideration of prevalence, clinical signs, and prognosis. Journal of the American Veterinary Medical Association 180 (1982) 261-265
9. Gill J., Heel R.C., and Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43 (1992) 69-110
10. Gonzalez G.A., Garcia S.M.V., La Mata G.M., and Mino F.G. Early-onset acute toxic hepatitis induced by intravenous amiodarone administration. Gastroenterologia y Hepatologia 25 (2002) 392-394
11. Huy C.P., Costa S., Nany S., Claude J.R., and Hamon M. Rapid microdetermination of amiodarone and its metabolite N-desethylamiodarone in plasma by high-performance liquid chromatography. Analytical Letters 24 (1991) 603-623
12. Kerin N.Z., Faitel K., and Naini M. The efficacy of intravenous amiodarone for conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Archives Internal Medicine 156 (1996) 49-53
13. Kochiadakis G.E., Igoumenidis N.E., Parthenakis F.I., Chlouverakis G.I., and Vardas P.E. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. Journal of the American College of Cardiology 33 (1999) 966-971
14. Kochiadakis G.E., Igoumenidis N.E., Solomou M.C., Kaleboubas M.D., Chlouverakis G.I., and Vardas P.E. Efficacy of amiodarone for the termination of persistent atrial fibrillation. American Journal of Cardiology 83 (1999) 58-61
15. Kodama I., Kamiya K., and Toyama J. Cellular electropharmacology of amiodarone. Cardiovascular Research 35 (1997) 13-29
16. Latini R., Tognoni G., and Kates R.E. Clinical pharmacokinetics of amiodarone. Clinical Pharmacokinetics 9 (1984) 136-156
17. Marr C., Reef V.B., Reimer J.M., Sweeney R.W., and Reid S.W. An echocardiographic study of atrial fibrillation in horses: before and after conversion to sinus rhythm. Journal of Veterinary Internal Medicine 9 (1995) 336-340
18. McGurrin K.M.J., Physick-Sheard P.W., Kenney D.G., Kerr C., Hanna W.J.B., Neto F.T., and Weese J.S. Transvenous electrical cardioversion in equine atrial fibrillation: technique and successful treatment of 3 horses. Journal of Veterinary Internal Medicine 5 (2003) 715-718
19. Nattel S., Davies M., and Quantz M. The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. Circulation 77 (1988) 200-208
20. Ohmura H., Nukada T., Mizuno Y., Yamaya Y., Nakayama T., and Amada A. Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation. Equine Veterinary Journal, Supplement (2000) 18-27
21. Pandozi C., Gentilucci G., Calo L., Castro A., Lamberti F., Loricchio M.L., Santini L., Magris B., Bulava A., Peichl P., and Santini M. Relations between monophasic action potential duration and refractoriness after cardioversion of persistent atrial fibrillation: results in wash-out and amiodarone-treated patients. Journal of the Italian Heart 4 (2003) 257-263
22. Patteson M.W., Gibbs C., Wotton P.R., and Cripps P.J. Echocardiographic measurements of cardiac dimensions and indices of cardiac function in normal adult thoroughbred horses. Equine Veterinary Journal, Supplement 19 (1995) 18-27
23. Patteson M. Two-dimensional and M-mode echocardiography. Cardiology of the horse. first ed. (1999) pp. 93-116, Chapter 7
24. Podrid P.J. Amiodarone: reevaluation of an old drug. Annals of Internal Medicine 122 (1995) 689-700
25. Reef V.B., Levitan C.W., and Spencer P.A. Factors affecting prognosis and conversion in equine atrial fibrillation. Journal of Veterinary Internal Medicine 2 (1988) 1-6
26. Reef V.B., and McGuirk S.M. Diseases of the cardiovascular system. Atrial fibrillation. Large Animal Internal Medicine. third ed. (2002) pp. 471-474, Chapter 28
27. Reef V.B., Reimer J.M., and Spencer P.A. Treatment of atrial fibrillation in horses: new perspectives. Journal of Veterinary Internal Medicine 9 (1995) 57-67
28. Rotmensch H.H., Belhassen B., Swanson B.N., Shoshani D., Spielman S.R., Greenspon A.J., Greenspan A.M., Vlasses P.H., and Horowitz L.M.N. Steady-state plasma amiodarone concentrations: relationship with antiarrhythmic efficacy and toxicity. Annales of Internal Medicine 101 (1984) 624-649
29. Sager P.T. New advances in class III antiarrhythmic drug therapy. Current Opinion in Cardiology 15 (2000) 41-53
30. Santoro L., Barbieri F., Nucciotti R., Battaglia F., Crispi F., Ragno M., Greco P., and Caruso G. Amiodarone-induced experimental acute neuropathy in rats. Muscle Nerve 15 (1992) 788-795
31. Singh B.N. Expanding indications for the use of Class III agents in patients at high risk for sudden death. Journal of Cardiovascular Electrophysiology 6 (1995) 887-900
32. Sugiyama A., Satoh Y., and Hashimoto K. Acute electropharmacological effects of intravenously administered amiodarone assessed in the vivo canine model. Japanese Journal of Pharmacology 87 (2001) 74-82
33. Tieleman R.G., Gosselink A.T., Crijns H.J., Van Gelder I.C., Van Den Berg M.P., De Kam P.J., Van Gilst W.H., and Lie K.I. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. The American Journal of Cardiology 79 (1997) 53-57
34. Trachsel D., Tschudi P., Portier C.J., Kuhn M., Thormann W., Scholtysik G., and Mevissen M. Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. Toxicology and Applied Pharmacology 195 (2004) 113-125
35. van Loon G., Blissitt K.J., Keen J.A., and Young L.E. Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. Equine Veterinary Journal 36 (2004) 609-614
36. van Loon G., Duytschaever M., Tavernier R., Fonteyne W., Jordaens L., and Deprez P. An equine model of chronic atrial fibrillation: methodology. The Veterinary Journal 164 (2002) 142-150
37. van Loon G., Jordaens L., Muylle E., Nollet H., and Sustonck B. Intracardiac overdrive pacing as a treatment of atrial flutter in a horse. The Veterinary Record 142 (1998) 301-303
38. van Loon G., Tavernier R., Duytschaever M., Fonteyne W., and Deprez P. Pacing induced sustained atrial fibrillation in a pony. Canadian Journal Veterinary Research 64 (2000) 254-258
39. Vardas P.E., Kochiadakis G.E., Igoumenidis N.I., Tsatsakis A.M., Simantirakis E.N., and Chlouverakis G.I. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 117 (2000) 1538-1545
40. Wijffels M.C., Kirchhof C.J., Dorland R., and Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92 (1995) 1954-1968